The Role of Program Directors in Treatment Practices: The Case of Methadone Dose Patterns in US Outpatient Opioid Agonist Treatment Programs

被引:4
|
作者
Frimpong, Jemima A. [1 ]
Shiu-Yee, Karen [2 ]
D'Aunno, Thomas [3 ]
机构
[1] Johns Hopkins Univ, Johns Hopkins Carey Business Sch, 100 Int Dr, Baltimore, MD 21202 USA
[2] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA
[3] NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10003 USA
基金
美国国家卫生研究院;
关键词
Methadone dose; opioid agonist treatment; program directors; program management; racial; ethnic variations; SUBSTANCE-ABUSE TREATMENT; INJECTION-DRUG USERS; SUBSTITUTION THERAPY; MAINTENANCE; DIVERSITY; DEPENDENCE; PERFORMANCE; MANAGEMENT; RETENTION; ATTITUDES;
D O I
10.1111/1475-6773.12558
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ObjectiveTo describe changes in characteristics of directors of outpatient opioid agonist treatment (OAT) programs, and to examine the association between directors' characteristics and low methadone dosage. Data SourceRepeated cross-sectional surveys of OAT programs in the United States from 1995 to 2011. Study DesignWe used generalized linear regression models to examine associations between directors' characteristics and methadone dose, adjusting for program and patient factors. Data CollectionData were collected through telephone surveys of program directors. Principal FindingsThe proportion of OAT programs with an African American director declined over time, from 29 percent in 1995 to 16 percent in 2011. The median percentage of patients in each program receiving <60mg/day declined significantly, from 48.5 percent in 1995 to 29 percent in 2005 and 23 percent in 2011. Programs with an African American director were significantly more likely to provide low methadone doses than other programs. This association was even stronger in programs with an African American director who served populations with higher percentages of African American patients. ConclusionsDemographic characteristics of OAT program directors (e.g., their race) may play a key role in explaining variations in methadone dosage across programs and patients. Further research should investigate the causal pathways through which directors' characteristics affect treatment practices. This may lead to new, multifaceted managerial interventions to improve patient outcomes.
引用
收藏
页码:1881 / 1907
页数:27
相关论文
共 29 条
  • [21] Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule
    Jordana Laks
    Jessica Kehoe
    Natalija M. Farrell
    Miriam Komaromy
    Jonathan Kolodziej
    Alexander Y. Walley
    Jessica L. Taylor
    Addiction Science & Clinical Practice, 16
  • [22] Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients
    Burgess-Hull, Albert J.
    Smith, Kirsten E.
    Schriefer, Destiny
    Panlilio, Leigh, V
    Epstein, David H.
    Preston, Kenzie L.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 226
  • [23] Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs
    Jones, Christopher M.
    Compton, Wilson M.
    Han, Beth
    Baldwin, Grant
    Volkow, Nora D.
    JAMA PSYCHIATRY, 2022, 79 (09) : 932 - +
  • [24] Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets
    Amiri, Solmaz
    Hirchak, Katherine
    Lutz, Robert
    McDonell, Michael G.
    McPherson, Sterling M.
    Roll, John M.
    Amram, Ofer
    DRUG AND ALCOHOL DEPENDENCE, 2018, 193 : 63 - 68
  • [25] Toward patient-tailored therapy in agonist opioid treatment: The role of psychopathology, craving behavioural covariates, stress reaction and methadone blood concentration. A case series
    Maremmani, Angelo G., I
    Bacciardi, Silvia
    Maremmani, Icro
    Della Rocca, Filippo
    Lamanna, Francesco
    Socci, Chiara
    Cerrai, Elisa
    Zallocco, Lorenzo
    Cerniglia, Luca
    Cimino, Silvia
    Giusti, Laura
    Lucacchini, Antonio
    Protti, Michele
    Mercolini, Laura
    Perugi, Giulio
    Mazzoni, Maria Rosa
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2020, 22 (06) : 57 - 72
  • [26] Prescription drug monitoring program utilization among 15 US opioid treatment programs (vol 85, pg 17, 218)
    Matusow, Harlan
    Rosenblum, Andrew
    Parrino, Mark
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 87 : 86 - 86
  • [27] Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study
    Bakouni, Hamzah
    Haquet, Lexie
    Socias, M. Eugenia
    Le Foll, Bernard
    Lim, Ron
    Ahamad, Keith
    Jutras-Aswad, Didier
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (02) : 167 - 173
  • [28] Rapid Overlap Initiation Protocol Using Low Dose Buprenorphine for Opioid Use Disorder Treatment in an Outpatient Setting: A Case Series
    Suen, Leslie W.
    Lee, Trevor G.
    Silva, Michael
    Walton, Paulette
    Coffin, Phillip O.
    Geier, Michelle
    Soran, Christine S.
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (05) : 534 - 540
  • [29] Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs
    Heo, Moonseong
    Pericot-Valverde, Irene
    Rennert, Lior
    Akiyama, Matthew J.
    Norton, Brianna L.
    Gormley, Mirinda
    Agyemang, Linda
    Arnsten, Julia H.
    Litwin, Alain H.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : 2093 - 2100